TOKYO--(BUSINESS WIRE)--May 31, 2023--
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo Japan, President and Representative Director: Daikichiro Kobayashi) announces that Adcock Ingram Pharma Private Limited (Headquarters: Bengaluru India, Managing Director: Y.A. Chowdary), an affiliated company of Medreich Limited (Headquarters: Bengaluru India, Managing Director: Pankaj Garg), has completed construction of a new manufacturing facility in Bengaluru, India, to enhance its production capacity of the contract manufacturing organization (CMO) business.
Adcock Ingram Pharma Private Limited, established in 2021, is a wholly-owned subsidiary of Adcock Ingram Limited that is a joint venture between Adcock Ingram Holdings Ltd., in South Africa, and Medreich Limited.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005041/en/
Image of the new manufacturing facility (Photo: Business Wire)
The new manufacturing facility has three floors above ground, a total floor area of 7,878 m 2, having an annual production capacity of 750 million tablets, 75 million sachets, and 4 million bottles, so that Adcock Ingram Pharma Private Limited can manufacture and supply pharmaceutical products not only for the Adcock Ingram Group in South Africa, but also for other clients.
The Meiji Group's Pharmaceutical Segment, in its "2023 Medium-Term Business Plan", has set an agenda to "Expand CMO/CDMO business" in its business strategies, in which Medreich Limited and Adcock Ingram Limited are regarded as the core companies of the CMO business. We will continue to optimize our production bases in Japan and overseas to strengthen our production system and establish the one for stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world.
*Overview of the new manufacturing facility | |
(1) Location | 41/42, Bommasandra Industrial Area, Anekal Taluk, Bangalore 560 099, India |
(2) Site area | Approx. 8,000m 2 |
(3) Total floor area | Approx. 7,878m 2 |
(4) Construction costs | Approx. JPY 2.21 billion |
(5) Production capacity (annual) | Tablets: 750 million tablets |
(6) Start of commercial productions | January 2024 |
*About Adcock IngramHoldings Ltd.
Adcock Ingram Holdings Ltd. is a leading South African pharmaceutical manufacturer, founded in 1891. Adcock Ingram Holdings Ltd. manufactures, markets and distributes a wide range of healthcare and consumer products, and is a leading supplier to both the private and public sectors of the market.
*: For further information, please visit the website at: www.adcock.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20230530005041/en/
CONTACT: Contact to
Meiji Seika Pharma Co., Ltd.
Kensuke Hata
General Manager
Medreich Operations Dept.
Telephone: +81-3-3273-6030
E-mail :pr-pharma@meiji.com
KEYWORD: ASIA PACIFIC SOUTH AFRICA INDIA JAPAN AFRICA
INDUSTRY KEYWORD: MANUFACTURING OTHER MANUFACTURING OTHER HEALTH HEALTH PHARMACEUTICAL
SOURCE: Meiji Seika Pharma Co., Ltd.
Copyright Business Wire 2023.
PUB: 05/31/2023 02:00 AM/DISC: 05/31/2023 02:01 AM
http://www.businesswire.com/news/home/20230530005041/en
